|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Cancer | |||||
| Anorexia | |||||
| Taste Disorders | |||||
| Olfactory Disorders | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Disease | |||||
| 3 | More general conditions related to this trial | ||||
| Nervous System Diseases | |||||
| Neurologic Manifestations | |||||
| Pathologic Processes | |||||
| Sensation Disorders | |||||
| Signs and Symptoms | |||||
| Signs and Symptoms, Digestive | |||||
| 4 | Interventions listed in this trial | ||||
| Marinol (Dronabinol) | |||||
| Placebo | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Tetrahydrocannabinol | |||||
| 6 | More general drug interventions related to this trial | ||||
| Analgesics | |||||
| Analgesics, Non-Narcotic | |||||
| Central Nervous System Agents | |||||
| Hallucinogens | |||||
| Peripheral Nervous System Agents | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Psychotropic Drugs | |||||
| Sensory System Agents | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| Alberta Cancer Board | |||||